Does Boston Scientific’s 2026 Double-Digit Sales Outlook and Leadership Shift Change The Bull Case For BSX?

Simply Wall St.02-14

Boston Scientific’s fourth-quarter 2025 results, reported on February 4, 2026, showed sales rising to US$5,286 million and net income to US$672 million, alongside full-year sales of US$20.07 billion ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611916140?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","is_english":true,"pubTime":"2026-02-14 00:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611916140","market":"nz","top_or_hot":-1,"title":"Does Boston Scientific’s 2026 Double-Digit Sales Outlook and Leadership Shift Change The Bull Case For BSX?","media":"Simply Wall St.","content":"<div>\n<p>Boston Scientific’s fourth-quarter 2025 results, reported on February 4, 2026, showed sales rising to US$5,286 million and net income to US$672 million, alongside full-year sales of US$20.07 billion ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/does-boston-scientifics-2026-double-digit-sales-outlook-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Boston Scientific’s 2026 Double-Digit Sales Outlook and Leadership Shift Change The Bull Case For BSX?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Boston Scientific’s 2026 Double-Digit Sales Outlook and Leadership Shift Change The Bull Case For BSX?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-14 00:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/does-boston-scientifics-2026-double-digit-sales-outlook-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Boston Scientific’s fourth-quarter 2025 results, reported on February 4, 2026, showed sales rising to US$5,286 million and net income to US$672 million, alongside full-year sales of US$20.07 billion ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/does-boston-scientifics-2026-double-digit-sales-outlook-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/does-boston-scientifics-2026-double-digit-sales-outlook-and","article_id":"2611916140","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/does-boston-scientifics-2026-double-digit-sales-outlook-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611916140","pubTimestamp":1771000367,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Boston Scientific’s fourth-quarter 2025 results, reported on February 4, 2026, showed sales rising to US$5,286 million and net income to US$672 million, alongside full-year sales of US$20.07 billion and net income of US$2.90 billion, while director Yoshiaki Fujimori later confirmed he will not stand for re-election at the 2026 Annual Meeting.\nThe company coupled this earnings report with guidance calling for double-digit reported and organic net sales growth in 2026, even as investors...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"波士顿科学公司2026年两位数的销售前景和领导层变动会改变BSX的牛市吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5},"content_text":"Boston Scientific’s fourth-quarter 2025 results, reported on February 4, 2026, showed sales rising to US$5,286 million and net income to US$672 million, alongside full-year sales of US$20.07 billion and net income of US$2.90 billion, while director Yoshiaki Fujimori later confirmed he will not stand for re-election at the 2026 Annual Meeting. The company coupled this earnings report with guidance calling for double-digit reported and organic net sales growth in 2026, even as investors focused on softer trends in certain U.S. electrophysiology and WATCHMAN segments and the upcoming transition in leadership of its Risk, Science and Technology Committee. We’ll now examine how Boston Scientific’s double-digit 2026 sales guidance and segment-level concerns affect the existing investment narrative. Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.AdvertisementBoston Scientific Investment Narrative RecapTo own Boston Scientific, you need to be comfortable with a story built around continued adoption of its minimally invasive cardiac and MedSurg therapies, while accepting execution and reimbursement risk. The latest earnings beat and double-digit 2026 sales guidance support that thesis, and the market’s sharp negative reaction to softer U.S. electrophysiology and WATCHMAN trends does not appear to materially change the near term catalyst around broader portfolio growth. The most relevant recent update here is the company’s 2026 guidance, which calls for 10.5% to 11.5% reported and 10.0% to 11.0% organic net sales growth. That outlook sits against ongoing cost and regulatory headwinds, including tariffs and potential U.S. reimbursement pressure on left atrial appendage closure, which could influence how much of that top line converts into profit. Yet behind the growth story, investors should be aware of the reimbursement risk around key therapies like WATCHMAN and how... Read the full narrative on Boston Scientific (it's free!)Boston Scientific's narrative projects $25.4 billion revenue and $4.8 billion earnings by 2028. This requires 11.1% yearly revenue growth and a $2.3 billion earnings increase from $2.5 billion today.Uncover how Boston Scientific's forecasts yield a $108.66 fair value, a 47% upside to its current price.Exploring Other PerspectivesBSX 1-Year Stock Price Chart Six members of the Simply Wall St Community currently see Boston Scientific’s fair value between US$82.65 and US$108.66, reflecting a wide spread of personal models. You can weigh those views against the company’s own outlook for double digit 2026 sales growth and decide how execution on advanced therapies might shape Boston Scientific’s longer term performance.Explore 6 other fair value estimates on Boston Scientific - why the stock might be worth just $82.65!Build Your Own Boston Scientific NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.Interested In Other Possibilities?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Uncover the next big thing with 27 elite penny stocks that balance risk and reward.AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Boston Scientific might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611916140","isCrawlerRequest":true}